secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2023-09-18T23:59:59+00:00
Accession:  0001558370-23-015840
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris reports positive Phase 1 MAD data for ATI-2138; advances to Phase 2a in ulcerative colitis
--------------------------------------------------------------------------------

- ATI-2138 well tolerated in 60-subject MAD trial; no serious adverse events; mild headache and diarrhea only events in >1 subject.
- Dose-proportional PK and near-maximal inhibition of ITK and JAK3 biomarkers achieved at 30 mg total daily dose.
- Company to start Phase 2a proof-of-concept in ulcerative colitis in early 2024; evaluating second PoC in another T-cell mediated disease.
- CEO highlights KINect discovery engine; upcoming Phase 2 data for zunsemetinib (RA) and ATI-1777 (atopic dermatitis) expected late 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023015840/0001558370-23-015840-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023015840/acrs-20230918x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-015840

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer